: GWPH shareholders received $200.00 in cash and $20.00 in Jazz ordinary shares for each GW American Depositary Share (ADS).

: Integration of GW has diversified Jazz's neuroscience portfolio, with Epidiolex contributing significantly to its revenue. Current Market Data for Jazz Pharmaceuticals (JAZZ)

Monitor institutional holdings and earnings reports on .

As of late April 2026, Jazz Pharmaceuticals continues to trade on the NASDAQ. You can track its performance on major financial platforms: View real-time quotes on . Check analyst ratings and fair value on Investing.com .

: The deal was valued at approximately $7.2 billion .

: Following the close of the transaction on May 5, 2021 , GWPH shares were delisted from the NASDAQ. How to Invest in GW Pharmaceuticals' Legacy

Are you currently facing a security breach?

Seek urgent assistance from our security operations center! Implement the recommended actions without delay while we address the situation.

Here are the recommended immediate next actions: